A protocol to support the weight-of-evidence for human carcinogenicity assessment of pharmaceuticals

This week we are pleased to welcome Dr. Arianna Bassan as a guest contributor to the blog. The recently published draft addendum of the ICH S1B guideline1 introduces a weight-of-evidence (WoE) approach to assess human carcinogenic potential of small molecule pharmaceuticals and determine whether a 2-year rat carcinogenicity study would add value. Application of this …

Availability of Original CPDB Data in Original Website Format

The Carcinogenicity Potency Data Bank or CPDB has long been an authoritative and trusted source of in vivo carcinogenicity data used in toxicological assessments worldwide. Unfortunately, for over 10 years the database has not been updated and all the original formatted and unaltered content is no longer publicly available. For many years, Leadscope has included …

Four papers accepted for publication

Over the last couple of weeks, we have received news that four papers, submitted earlier this year to the Journal of Computational Toxicology, have been accepted for publication. Developing Structure-Activity Relationships for N-Nitrosamine Activity1 This paper outlines N-Nitrosamine carcinogenic potency ranges and describes specific structural features that have clear effects on these ranges. It highlights …